Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.

This study examined monoclonal antibodies LT-1, LT-2, and LT-7, finding they can effectively detect certain antigens on T and B cells involved in various lymphoproliferative diseases, aiding in the diagnosis of both acute and chronic lymphoid neoplasias.

In this study, researchers prepared a humanized CXCL12 antibody for alopecia areata treatment, finding it significantly delayed disease onset in mice and reduced immune cell activation, suggesting potential as an immune modulatory therapy.

This study found that patients with alopecia areata have lower levels of sCD83, a protein which, when supplemented in a mouse model, reversed disease symptoms and supported regulatory T cell proliferation, possibly by interacting with IDO activity.

This study observed that expanding regulatory T cells in the skin of mice with alopecia areata did not reverse the condition, indicating that additional immunotherapy may be necessary.

This comprehensive review suggests that CD44 signaling plays a significant role in post-natal skin wound healing and scar formation, with potential for therapeutic approaches targeting CD44 to shift from fibrotic scarring towards regenerative healing, including wound regeneration and hair neogenesis.

This study found that targeting IL-6, IL-1, and CCR6 signaling pathways may effectively reduce irradiation-induced alopecia and dermatitis in radiotherapy patients.

This study found that CD1d is strongly expressed in human scalp skin and hair follicles, particularly in the anagen phase, suggesting a role in scalp immunology and potential implications for hair disorder treatment.

In this study, alopecia areata patients treated with diphencyprone showed a significant increase in CD8 lymphocytes around hair bulbs, which may be associated with hair regrowth.

This study found that selective deletion of Ctip2 in epidermal keratinocytes in adult mice leads to atopic dermatitis-like inflammation and suggests Ctip2 plays a crucial role in skin barrier maintenance and inflammatory regulation.

This study found that CD133-positive dermal papilla cells significantly enhanced hair growth in mice compared to CD133-negative cells, suggesting their potential for improving human hair follicle engineering.

This study found that platelet-secreted chemokines like CXCL7 are crucial for early neutrophil recruitment and efficient muscle regeneration in injured mice.

This study demonstrated that the immunomodulatory drug FTY720 may enhance the survival of allogeneic fat grafts in mice by reducing immune rejection and improving neovascularization.

This study found that the 3' UTR of JAM-A acts as a key competing endogenous RNA that supports dermal papilla cell function and hair follicle regeneration in alopecia areata.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

This study reports that LL-37 treatment enhances cell proliferation, migration, and secretion of regenerative factors in adipose-derived stem cells, potentially promoting hair growth in vivo.

This study found that in alopecia areata, epidermal γδ T cells and macrophages contribute to the disease alongside CD8 T cells, with the expression of BST2 marking interferon-driven immune activation in both mouse and human skin, which decreases following treatment with the JAK inhibitor tofacitinib.

TCDD changes skin gene expression and may harm skin health.

This study found that patients with active severe alopecia areata exhibited decreased CD200 expression on T and B lymphocytes, which may be linked to an imbalance in Th1/Th2 immune equilibrium.

This study found that topical treatment with 7DHC and BM15766 reduced hair growth in mice compared to those treated with Ethanol/DMSO, and hair did not recover after treatment ceased, alongside increased apoptotic cells and decreased expression of specific genes.

This study identifies a mechanism where dsRNA activates TLR3 to induce RA production, promoting hair follicle regeneration in mice and suggesting a potential role in human tissue regeneration.

This study reports that CD200R expression is significantly reduced in an experimental mouse model of scarring alopecia, suggesting a potential role for this pathway in immune regulation and hair follicle protection.

This pilot clinical study introduces DEC cells as a novel therapy for Duchenne muscular dystrophy, confirming safety and efficacy in seven patients up to 24 months post-treatment.

This study found that Dendrobium candidum polysaccharides might promote hair growth in mice, potentially by increasing VEGF mRNA expression.

This study reported that a newly developed hydrogel patch, designed to recruit regulatory T cells through ROS-triggered release of CCL22, improved wound healing and hair follicle regeneration in a diabetic mouse model by scavenging ROS, thereby protecting Tregs and suppressing Th17 cells.

This study identified CD28 as a promising drug target for treating alopecia areata, using a multi-omics approach to highlight its role in immune regulation and linking it to favorable safety profiles, thus offering a strategy for autoimmune target discovery.

The study found that the combined administration of regulatory T cells and rapamycin improved outcomes in an experimental model of chronic graft-versus-host disease.

This study suggests that chronic treatment with TPA in mouse skin selectively expands a keratinocyte subpopulation hyperinducible for ODC, which may be a key target for neoplastic transformation.